Real-world data analysis of post-COVID-19 condition risk in older patients

Liu, Ting-Hui; Huang, Po-Yu; Wu, Jheng-Yan; Chuang, Min-Hsiang; Hsu, Wan-Hsuan; Tsai, Ya-Wen; Tsai, Meng-Hsiu; Lai, Chih-Cheng

doi:10.1093/ageing/afad204

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, we measured the short-term outcomes - the composite of all-cause hospitalization or death within 30 days and the risk of post-COVID-19 conditions up to a year after COVID-19 diagnosis. The post-COVID-19 conditions were defined as the presence of any of the following ten symptoms, including chest/throat pain, abdominal symptoms, fatigue, headache, cognitive symptoms, myalgia, sleep disturbance, cough, and palpitation, using ICD-10 codes, as previous studies ( Taquet et al, 2021a ; Liu et al, 2023a ; Liu et al, 2023b ).…”

Section: Methodsmentioning

confidence: 99%

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders

Liu,

Liao,

Chang

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

ObjectivesThis study investigated the clinical effectiveness of molnupiravir for treating non-hospitalized COVID-19 patients with pre-existing psychiatric disorder.MethodsThis retrospective cohort study used the TriNetX research network to identify patients with psychiatric disorder who experienced non-hospitalized COVID-19 between 1 January 2022, and 1 May 2023. The propensity score matching (PSM) method was used to match patients receiving molnupiravir (treated group) with those who did not (untreated group). The outcome included short-term outcomes - the composite of all-cause hospitalization or death within 30 days and the risk of post-COVID-19 conditions up to a year after COVID-19 diagnosis.ResultsTwo groups of 9,421 patients, each with balanced baseline characteristics, were identified using the PSM method. During the 30-day follow-up, treated group was associated with a reduced risk of hospitalization or mortality compared to untreated group (HR, 0.760; 95% CI, 0.665–0.869). Compared to untreated group, treated group also exhibited a decreased risk of experiencing post-COVID-19 conditions, including chest/throat pain (HR, 0.615; 95% CI, 0.543–0.696), abnormal breathing (HR, 0.761; 95% CI, 0.687–0.884), abdominal symptoms (HR, 0.748; 95% CI, 0.674–0.831), fatigue (HR, 0.718; 95% CI, 0.638–0.808), headache (HR, 0.753; 95% CI, 0.665–0.852), cognitive symptoms (HR, 0.769; 95% CI, 0.630–0.940), myalgia (HR, 0.647; 95% CI, 0.530–0.789), cough (HR, 0.867; 95% CI, 0.770–0.978), and palpitation (HR, 0.641; 95% CI, 0.534–0.770) during the 1-year follow-up.ConclusionMolnupiravir could be associated with lower rates of all-cause hospitalization or death and also lower risk of post-COVID-19 condition among non-hospitalized COVID-19 patients with pre-existing psychiatric disorder.

show abstract

Section: Methodsmentioning

confidence: 99%

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders

Liu,

Liao,

Chang

et al. 2024

Front. Pharmacol.

Self Cite

View full text Add to dashboard Cite

show abstract

The Effectiveness of COVID‐19 Vaccination on Post‐Acute Sequelae of SARS‐CoV‐2 Infection Among Geriatric Patients

Chan,

Chen,

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

This study aims to evaluate the effectiveness of anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines in preventing the post‐acute sequelae of SARS‐CoV‐2 infection (PASC), commonly known as long COVID, and reducing all‐cause mortality among older patients. A retrospective cohort study was conducted using the TriNetX database. The study cohort consisted of older patients (age ≥ 65 years) with their first COVID‐19 illness between January 1, 2022, and May 31, 2024. Participants were divided into vaccinated and unvaccinated groups based on their vaccination status. Propensity score matching (PSM) was used to balance baseline characteristics. Cox regression models and log‐rank tests were applied to estimate the hazard ratio (HR) for PASC and all‐cause mortality during 30–180 days of follow‐up. The study included 189 059 geriatric patients who contracted SARS‐CoV‐2, with 5615 vaccinated and 183 444 unvaccinated. After PSM, each group contained 5615 patients. Vaccinated patients exhibited a significantly lower incidence of PASC symptoms (HR = 0.852, 95% CI: 0.778–0.933, p = 0.0005), particularly anxiety and depression, with a HR of 0.710 (95% CI: 0.575–0.878, p = 0.0015). Vaccination was also significantly associated with reduced all‐cause mortality (HR = 0.231, 95% CI: 0.136–0.394, p < 0.0001). The findings highlight the effectiveness of COVID‐19 vaccination in mitigating the development of PASC and decreasing mortality among older patients.

show abstract

The risk of geriatric syndromes in older COVID-19 survivors among the nonvaccinated population: a real world retrospective cohort study

Su,

Yang,

et al. 2024

Age and Ageing

View full text Add to dashboard Cite

Background We aimed to analyse the differences in the risk of geriatric syndromes between older adults with and without coronavirus disease 2019 (COVID-19). Methods We conducted a retrospective cohort study of patients from the US Collaborative Network in the TriNetX between January 1, 2020, and December 31, 2022. We included individuals aged older than 65 years with at least 2 health care visits who underwent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) tests during the study period. We excluded those with SARS-CoV-2 vaccination, diagnosis with neoplasm and geriatric syndromes before the index date, and death within 30 days after the index date. The index date was defined as the first date of the PCR test for SARS-CoV-2 during the study period. Hazard ratios (HRs) and 95% confidence intervals (CIs) for eight geriatric syndromes were estimated for propensity score-matched older adults with and without COVID-19. Subgroup analyses of sex and age were also performed. Results After propensity score matching, 315 826 patients were included (mean [standard deviation] age, 73.5 [6.4] years; 46.7% males and 51.7% females). The three greatest relative increases in the risk of geriatric syndromes in the COVID-19 cohort were cognitive impairment (HR: 3.13; 95% CI: 2.96–3.31), depressive disorder (HR: 2.72; 95% CI: 2.62–2.82) and pressure injury (HR: 2.52; 95% CI: 2.34–2.71). Conclusions The risk of developing geriatric syndromes is much higher in the COVID-19 cohort. It is imperative that clinicians endeavour to prevent or minimise the development of these syndromes in the post-COVID-19 era.

show abstract

Real-world data analysis of post-COVID-19 condition risk in older patients

Cited by 3 publications

References 22 publications

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders

Effectiveness of molnupiravir for treating COVID-19 in patients with psychiatric disorders

The Effectiveness of COVID‐19 Vaccination on Post‐Acute Sequelae of SARS‐CoV‐2 Infection Among Geriatric Patients

The risk of geriatric syndromes in older COVID-19 survivors among the nonvaccinated population: a real world retrospective cohort study

Contact Info

Product

Resources

About